Eltrapuldencel-T

N/A

Report date: 2024/12/23 15:39:19

Base Information

Drug NameEltrapuldencel-T

Drug Alias NameAutologous stem cell therapyCancer stem cellMelapuldencel-TMalignant melanoma stem cell therapyCLBS-20 +[9]

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSkin MelanomaMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCaladrius Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLisata Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsSkin MelanomaMelanoma

Other Information

ATC CodeN/A